Sader HS - Search Results

1

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).

Sader HS, Mendes RE, Duncan LR, Carvalhaes CG, Castanheria M. Sader HS, et al. J Antimicrob Chemother. 2022 Sep 30;77(10):2642-2649. doi: 10.1093/jac/dkac233. J Antimicrob Chemother. 2022. PMID: 35897129

2

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).

Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA, Doern GV. Gales AC, et al. Among authors: sader hs. J Antimicrob Chemother. 2000 Mar;45(3):295-303. doi: 10.1093/jac/45.3.295. J Antimicrob Chemother. 2000. PMID: 10702547

3

In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.

Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sader HS. Roland RK, et al. Among authors: sader hs. Braz J Infect Dis. 2000 Oct;4(5):226-35. Braz J Infect Dis. 2000. PMID: 11063554

4

Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program.

Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, Jones RN. Sader HS, et al. Braz J Infect Dis. 2001 Aug;5(4):200-14. doi: 10.1590/s1413-86702001000400006. Epub 2003 Mar 7. Braz J Infect Dis. 2001. PMID: 11712965

5

Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000).

Gales AC, Sader HS, Mendes RE, Jones RN. Gales AC, et al. Among authors: sader hs. Diagn Microbiol Infect Dis. 2002 Nov;44(3):313-8. doi: 10.1016/s0732-8893(02)00506-0. Diagn Microbiol Infect Dis. 2002. PMID: 12493179

6

Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States.

Gordon KA, Sader HS, Jones RN. Gordon KA, et al. Among authors: sader hs. Diagn Microbiol Infect Dis. 2003 Sep;47(1):377-83. doi: 10.1016/s0732-8893(03)00096-8. Diagn Microbiol Infect Dis. 2003. PMID: 12967754

7

Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY Antimicrobial Surveillance Program (1997-2000).

Mendes RE, Reis AO, Gales AC, Jones RN, Sader HS. Mendes RE, et al. Among authors: sader hs. Braz J Infect Dis. 2003 Oct;7(5):282-9. doi: 10.1590/s1413-86702003000500001. Epub 2004 Jan 22. Braz J Infect Dis. 2003. PMID: 14552736

8

Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.

Sader HS, Huynh HK, Jones RN. Sader HS, et al. Diagn Microbiol Infect Dis. 2003 Nov;47(3):547-50. doi: 10.1016/s0732-8893(03)00158-5. Diagn Microbiol Infect Dis. 2003. PMID: 14596974

9

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).

Jones RN, Sader HS, Beach ML. Jones RN, et al. Among authors: sader hs. Int J Antimicrob Agents. 2003 Dec;22(6):551-6. doi: 10.1016/s0924-8579(03)00245-0. Int J Antimicrob Agents. 2003. PMID: 14659650

10

In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.

Sader HS, Johnson DM, Jones RN. Sader HS, et al. Antimicrob Agents Chemother. 2004 Jan;48(1):53-62. doi: 10.1128/AAC.48.1.53-62.2004. Antimicrob Agents Chemother. 2004. PMID: 14693518 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

555 results

Search Page